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During genome replication, polymerase epsilon (Pol ε) acts as the major leading-strand DNA polymerase. Here we report the identifica-
tion of biallelic mutations in POLE, encoding the Pol ε catalytic subunit POLE1, in 15 individuals from 12 families. Phenotypically, these
individuals had clinical features closely resembling IMAGe syndrome (intrauterine growth restriction [IUGR], metaphyseal dysplasia,
adrenal hypoplasia congenita, and genitourinary anomalies in males), a disorder previously associated with gain-of-function mutations
in CDKN1C. POLE1-deficient individuals also exhibited distinctive facial features and variable immune dysfunction with evidence of
lymphocyte deficiency. All subjects shared the same intronic variant (c.1686þ32C>G) as part of a common haplotype, in combination
with different loss-of-function variants in trans. The intronic variant alters splicing, and together the biallelic mutations lead to cellular
deficiency of Pol ε and delayed S-phase progression. In summary, we establish POLE as a second gene in which mutations cause IMAGe
syndrome. These findings add to a growing list of disorders due to mutations in DNA replication genes that manifest growth restriction
alongside adrenal dysfunction and/or immunodeficiency, consolidating these as replisome phenotypes and highlighting a need for
future studies to understand the tissue-specific development roles of the encoded proteins.DNA replication is a fundamental cellular process necessary
to ensure the faithful transmission of genetic information.
In eukaryotes, threehighly conservedDNApolymerases, po-
lymerase epsilon, delta, and alpha, act in concert at the repli-
cation fork. Polymerase epsilon (Pol ε) is the major enzyme
responsible for the synthesis of the leading strand1 and is
consequently an essential gene.2 POLE encodes the catalytic
subunitofPol ε (POLE1), and somatic andgermlinemissense
mutations affecting theproofreadingdomainofPOLE1have
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 2018 The Authors. This is an open access article under the CC BY-NC-ND lMicrocephalic primordial dwarfism comprises a group
of prenatal-onset extreme growth disorders characterized
by intrauterine growth retardation, short stature, and
microcephaly. Genes involved in cell cycle progression,
including multiple components of the replication
licensing machinery, have been identified as monogenic
causes of this disorder.7–11 As the molecular basis for
many affected individuals remains to be determined, we
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Table 1. Biallelic POLE Mutations (GenBank: NM_006231.3)
ID Fam Sex
Allele 1 Allele 2
Mat
Allele
Pat
Allele
Country
of Origin
Nucleotide
Change
Amino Acid
Consequence MAF
Nucleotide
Change
Amino Acid
Consequence MAF
P1 1 M c.2091dupC p.Phe699Valfs*11 0 c.1686þ32C>G p.Asn563Valfs*16 0.000071 1 2 UK
P2 1 F c.2091dupC p.Phe699Valfs*11 0 c.1686þ32C>G p.Asn563Valfs*16 0.000071 1 2 UK
P3 2 M c.62þ1G>A Essential Splice
Site Intron 1
0 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 Ireland
P4 3 F c.5940G>A p.Trp1980* 0.000016 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 Australia
P5 4 M c.4728þ1G>T Essential Splice
Site Intron 36
0 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 USA
P6 5 F c.3264_3275þ13del Essential Splice
Site Intron 26
0.000016 c.1686þ32C>G p.Asn563Valfs*16 0.000071 1 2 Canada
P7 6 M c.1A>T p.? 0.000081 c.1686þ32C>G p.Asn563Valfs*16 0.000071 n/a n/a USA
P8 7 M c.1A>T p.? 0.000081 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 Ireland
P9 7 F c.1A>T p.? 0.000081 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 Ireland
P10 8 F c.3019G>C p.Ala1007Pro 0.000009 c.1686þ32C>G p.Asn563Valfs*16 0.000071 1 2 Ireland
P11 9 F c.5265delG Ile1756Serfs*5 0 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 Australia
P12 9 M c.5265delG Ile1756Serfs*5 0 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 Australia
P13 10 F c.2049C>G p.Tyr683* 0.000028 c.1686þ32C>G p.Asn563Valfs*16 0.000071 1 2 Australia
P14 11 M c.6518_6519delCT p.Ser2173Phefs*130 0.000089 c.1686þ32C>G p.Asn563Valfs*16 0.000071 2 1 USA
P15 12 M c.801þ2T>C Essential Splice
Site Intron 8
– c.1686þ32C>G p.Asn563Valfs*16 0.000071 1 2 USA
Abbreviations: ID, individual number; Fam, family number; Mat, maternal; Pat, paternal; n/a, not available. All subjects harbored a loss-of-function mutation in
combination with an intronic variant on the alternate allele identified as part of a shared haplotype and found to alter splicing in RNA studies. MAF indicates minor
allele frequency in European (non-Finnish) population observed in gnomAD. None of the variants were present in any Non-European population in gnomAD.Whole-genome sequencing (WGS) of 48 individuals
with microcephalic primordial dwarfism identified hetero-
zygous POLE (GenBank: NM_006231.3) loss-of-function
(LoF) variants in three subjects (P1, P3, P4; Table 1).
These LoF variants were significantly enriched in our
cohort compared to a control WGS dataset (GnomAD,12
p ¼ 5.1 3 105, Fisher’s exact test, Table S1). As these var-
iants were present in the unaffected parents, the
WGS data were further evaluated and a second rare in-
tronic variant in POLE identified, c.1686þ32C>G (dbSNP:
rs762985435). This was present in trans with the LoF mu-
tation in all three probands (Table 1). Targeted sequencing
of POLE and interrogation of existing whole-exome
sequencing (WES) data in additional cases of primordial
dwarfism identified five additional subjects compound
heterozygous for LoF alleles and the c.1686þ32C>G
variant (P5–P9, Table 1). Notably, a clinical diagnosis of
IMAGe syndrome (GeneReviews in Web Resources)
(MIM: 614732) had been considered in individuals P1
and P3, with adrenal failure also reported in P5, P6, and
P7. We therefore investigated cases of IMAGe syndrome
drawn from other cohorts without an existing molecular
diagnosis (i.e., CDKN1C mutation negative). These
included three previously published IMAGe-affected case
subjects.13,14 Analysis of their WGS data identified addi-
tional POLE LoF variants inherited in trans with the in-The American Jourtronic variant in individuals P11–P15 (Table 1). The
c.1686þ32C>G variant was part of a common haplotype
in all individuals where WES/WGS performed, extending
over 921 kbp (Figure S2, chr12:132341818–133263107,
GRCh38). In P10 a missense variant (c.3019G>C) encod-
ing a p.Ala1007Pro substitution was found, at a residue
conserved to yeast (Figure S1) within the polymerase
domain of the protein (Figure 1). All variants identified
were sufficiently rare (MAF < 0.000112) and, where DNA
available, segregation in families was consistent with an
autosomal recessively inherited disorder (Table 1).
Phenotypically, affected individuals had severe growth
failure of prenatal onset (Figure 2, Table S2). IUGR was pre-
sent in all case subjects (birth weight was 3.0 5 0.8 SD)
with significant short stature evident postnatally (height
8.15 2.4 SD). While head circumference was also signif-
icantly reduced (OFC 5.45 1.5 SD), this was less severe,
resulting in a relative macrocephaly. Those affected had a
common facial appearance with micrognathia, crowded
dentition, long thin nose, short wide neck, and small,
low-set, posteriorly rotated ears (Figure 2). 12 individuals
had adrenal insufficiency and all affected males had geni-
tourinary abnormalities including bilateral cryptorchidism
and/or hypospadias, with the majority of case subjects ful-
filling clinical criteria for IMAGe syndrome (GeneReviews
in Web Resources; Table 2, Table S3, Supplemental Note).nal of Human Genetics 103, 1038–1044, December 6, 2018 1039
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Figure 1. Mutations Causing POLE-Asso-
ciated IMAGe Syndrome Are Distinct
from Mutations Conferring a Non-syn-
dromic Susceptibility to Cancer
Schematic of the POLE gene, which en-
codes POLE1, the catalytic subunit of
DNA polymerase epsilon. Domains: Pol,
polymerase; Exo, exonuclease. Mutations
identified in POLE subjects indicated
above gene and protein (green). Recurrent
intronic mutation underlined. For com-
parison, heterozygous germline missense
mutations located in the exonuclease
domain predisposing to colorectal can-
cer and other malignancies highlighted
below (red).Osteopenia and developmental dysplasia of the hip (DDH)
were frequently observed and cafe´-au-lait patches were
notably present in a third of individuals.
A single homozygous intronic variant (c.4444þ3A>G)
in POLE has previously been reported to be associated
with immunodeficiency, lymphopenia, and short stature
(facial dysmorphism, immunodeficiency, livedo, and short
stature, aka FILS syndrome [MIM: 615139]).15,16 Five
affected individuals identified in this study also had
increased susceptibility to respiratory tract infections,
with lymphocyte subset deficiencies and/or IgM hypogam-
maglobinemia identified in P1, P3, P4, P8, P9, P14, and P15
(Table 2, Table S4). Deficiency of natural killer cells was
present in P1, P3, and P8. P1 had the most profound im-
munodeficiency, developing CMV pneumonitis and then
subsequently developed EBV haemophagocytic lympho-
histiocytosis, requiring an allogeneic bone marrow trans-
plant. Notably, this subject’s sister (P2), who had the
same compound heterozygous POLE mutations, died at
22 months from HSV infection. Therefore, our findingsA
Figure 2. Individuals with Biallelic POLE Mutations Have Severely
Gestalt
(A) Photographs of POLE-deficient subjects demonstrating facia
photography.
(B and C) Severe pre-natal onset growth restriction occurs in POLE-d
(B) Adult POLE-deficient subject next to a control individual of aver
(C) Growth is severely impaired pre- and postnatally. Z-scores (stan
weight and postnatal height and head circumference (OFC). Dashe
individual subject data points; red bars, mean values.
1040 The American Journal of Human Genetics 103, 1038–1044, Decestablish that the phenotype spectrum of biallelic POLE
mutations extends from IMAGe syndrome to include
immunodeficiency, in line with the phenotype and
pathogenicity of the previously reported c.4444þ3A>G
mutation.15,16
To establish whether the c.1686þ32C>T variant affected
the POLE transcript, RNA studies were performed on pri-
mary fibroblast lines derived from two subjects (P1, P3).
RT-PCR using primers spanning POLE intron 15 demon-
strated the presence of a larger PCR product (Figure 3),
which capillary sequencing established to be due to
retention of part of intron 15 within POLE transcripts
(Figure S3). A minigene assay was then performed to assess
splicing of this genomic segment and to directly confirm
the contribution of the c.1686þ32C>G variant. This
demonstrated that the c.1686þ32C>G variant markedly
impaired splicing of the usual exon 15 splice donor site,
leading to preferential use of a downstream alternate splice
donor site in intron 15, although some canonical splicing
also occurred (Figure 3). The inclusion of 47 bp of intronicCB Prenatal Postnatal
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Table 2. Individuals with Biallelic Mutations in POLE Were Clinically Diagnosed with Primordial Dwarfism and Features of IMAGe
Syndrome
ID Fam Sex Age I MþSI A Ge I Other Features
P1 1 M 18 Y Y Y Y Y scoliosis, osteopenia, small patella,
seizures, gastrostomy, eczema
P2 1 F 1 Y Y Y – Y –
P3 2 M 7 Y Y Y Y Y midline accessory incisor, osteopenia,
infant eczema
P4 3 F 50 Y Y N – Y IgM paraproteinaemia
P5 4 M 12 Y NA Y Y Y hypopituitarism, T cell lymphoma,
gastrostomy, absent patella
P6 5 F 10 Y Y Y – Y bilat coxa valga, 11 ribs, 6 lumbar
vertebrae, scoliosis, gastrostomy,
infant eczema
P7 6 M 13 Y Y Y Y N hypopituitarism, atrial septal defect,
brachydactyly, gastrostomy
P8 7 M 3 Y Y N Y Y DDH, gastrostomy
P9 7 F 2 Y Y N – Y DDH, gastrostomy
P10 8 F 39 Y Y Y – N DDH, 11 ribs, clinodactyly,
osteopenia, cafe´ au lait patches
P11 9 F 0.2 Y NA Y – Y cafe´ au lait patch
P12 9 F 12 Y Y Y – N –
P13 10 M 22 Y Y Y Y N DDH, cafe´ au lait patch
P14 11 F 18 Y Y Y – Y gastrostomy, hypercalaemia in
infancy, cafe´ au lait patches,
DDH, kyphoscoliosis
P15 12 M 31 Y NA Y Y Y cafe´ au lait patches, seizures,
osteopenia, osteoporosis, nodular
sclerosis, Hodgkin’s lymphoma
Abbreviations: ID, individual number; Fam, family number; I, intrauterine growth restriction; MþSI, skeletal involvement: metaphyseal dysplasia or other skeletal
abnormalities reported in CDKN1C IMAGe-affected individuals (NA, not assessed); A, adrenal insufficiency; Ge, genitourinary abnormalities in males (– female,
genitourinary anomalies not applicable); I, immunodeficiency, either increased susceptibility to infections or documented lymphopenia/hypogammaglobine-
mia; DDH, developmental dysplasia of the hip; Y, yes; N, no. See Tables S1–S4 for extended clinical data and morphometrics.DNA in the variant transcript results in a frameshift, which
would lead to premature termination (p.Asn563Valfs*16).
While this transcript might be targeted for nonsense-medi-
ated decay, any translated protein would also be non-func-
tional given that this frameshift occurs at the start of the
polymerase catalytic domain. Combined with a LoF muta-
tion on the second allele, substantial reduction in POLE1
was therefore anticipated. Subsequent immunoblotting
of total protein extracts from of primary fibroblasts from
affected subjects confirmed that POLE1 levels were indeed
markedly depleted (Figure 3; 5%5 3% for P1 and 11%5
4% P3, relative to the mean of both control subjects and
normalized to vinculin loading control; mean 5 SD for n
¼ 2 independent experiments), with chromatin fraction-
ation experiments demonstrating reduction of POLE1 in
both soluble and chromatin-bound fractions (Figure S4).
Taken together with the consistent clinical phenotype
across case subjects, we concluded that the identified
POLE variants were pathogenic, resulting in a phenotype
spectrum substantially overlapping IMAGe syndrome.
In keeping with an essential requirement for POLE in
eukaryotes,2 the ‘‘leaky’’ c.1686þ32C>G splice mutationThe American Jourpermitted residual expression of functional POLE1 in all
case subjects. This mutation in trans with truncating muta-
tions would then be expected to lead to marked but partial
loss of function. As POLE encodes POLE1, the catalytic sub-
unit of the major leading-strand DNA polymerase Pol ε,
reduced chromatin levels of POLE1 would therefore be ex-
pected to impact on the availability of Pol εDNApolymerase
activity during its canonical function in DNA replication.
Consistent with this, time-course FACS analysis demon-
strated delayed cell-cycle progression of BrdU-labeled pri-
mary fibroblasts from P1 and P3, indicative of impaired
S-phase progression (Figure 3). While no viable model of
POLE1 deficiency exists, a Pole4/ mouse has been gener-
ated, which is similarly deficient for the Pol ε holoen-
zyme.17 This mouse also has significant prenatal onset
growth failure, reduced brain size, and markedly reduced
lymphocyte levels. Analysis of embryonic fibroblasts derived
from this mouse alongside POLE primary human fibroblasts
(derived from P1 and P3 in this study) established that in
both cases Pol ε deficiency leads to reduced levels of chro-
matin-loaded Pol ε complexes, resulting in replication stress
arising from reducednumbers of active replication origins.17nal of Human Genetics 103, 1038–1044, December 6, 2018 1041
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Figure 3. Common Intronic Variant Identified Causes Aberrant Splicing and POLE-Deficient Cells Show Deficiency of Polymerase
Epsilon and Slowed S-phase Progression
(A) The c.1686þ32C>G mutation causes aberrant splicing of intron 15 in subject cells. RT-PCR of POLE transcripts from primary fibro-
blasts. Primers indicated by arrows in schematic. P1, P3, POLE-deficient subjects; C1, C2, control subjects.
(B) Minigene assay demonstrating that aberrant splicing is a direct consequence of the c.1686þ32C>G mutation. þve control, point
mutation in splice donor site, c.1686þ1G>A. 50 & 30 indicate artificial vector-associated exons.
(C) POLE1 levels are markedly reduced in subject fibroblasts. Immunoblot of total cell extracts. POLE1 antibody raised against AA1-176.
Vinculin, loading control. * non-specific band.
(D and E) Fibroblast cells from affected individuals exhibit delayed S phase progression. Schematic, experimental set-up.
(D) Representative FACS plots.
(E) Quantification of n ¼ 3 affected and n ¼ 3 control cell lines from representative experiment (of n ¼ 3 expts with nR 2 biological
replicates per group). Mid-S-phase mean (5SEM) BrdU-labeled cells, normalized to t ¼ 0 time point are plotted for each group. p value,
two-way ANOVA.IMAGe syndrome has previously been found to be
caused by dominant gain-of-function mutations in the im-
printed gene, CDKN1C.18,19 Here, we establish mutations
of POLE as an autosomal-recessive cause of the IMAGe
phenotype. These mutations contrast with heterozygous
germline and somatic cancer-predisposing mutations that
affect the exonuclease domain of POLE13–6 (Figure 1).
IMAGe and cancer mutations are likely to have differing
functional outcomes, respectively leading to deficient
DNA replication or to impaired proof-reading.20 Hence, a
similar cancer predisposition in POLE1-deficient individ-
uals or POLE heterozygous carriers cannot be assumed.
However, P5 developed a T cell lymphoma at age 11 and
P15 developed Hodgkin’s lymphoma at age 28. Given
also the increased lymphoma rates in Pole4/ mice,17
POLE1 deficiency may therefore confer an increased risk
of lymphoma.
All CDKN1C IMAGe mutations cluster within its prolif-
erating cell nuclear antigen (PCNA) binding domain,18,19
targeting the PCNA binding PIP-box motif.21 As PCNA
loads with Pol ε at replication initiation (Figures 4 and
S5), the phenotypic overlap with POLE-associated IMAGe
syndrome suggests a mechanistic link. Supporting this
notion, biochemical studies of aXenopus homolog suggests
that CDKN ubiquitination and subsequent degradation1042 The American Journal of Human Genetics 103, 1038–1044, Decis mediated by PCNA/polymerase loading23,24 (Fig-
ure S5). Furthermore, single homozygous mutations in
MCM411,25 (MIM: 609981) and POLE226 have been associ-
ated with IUGR and short stature, alongside immunodefi-
ciency, respectively with and without adrenal failure.
Likewise, several families with GINS1 biallelic mutations
have been reported to be associated with pre/postnatal
growth restriction, chronic neutropenia, and NK cell defi-
ciency (MIM: 610608).10 Hence, the identification of a
cohort of individuals with POLE mutations that encom-
passes all these features consolidates this as a group of
replisome-associated disorders (Figure 4, Table S5). Replica-
tion stress and p53-mediated cell death17 likely explain the
immunodeficiency as well as global growth failure in
POLE1-deficient individuals. However, why impaired repli-
some function should have a particularly strong impact on
specific lymphoid lineages (T/B cells in POLE1/2-deficient
subjects and NK cells in MCM4/GINS1-deficient individ-
uals) or on adrenal cortical cells is unclear. Notably,
another distinct form of primordial dwarfism, Meier-Gor-
lin syndrome (defined by the triad of short stature, patella
hypoplasia, and microtia [MIM: 224690]) is also caused by
biallelic (or de novo) mutations in genes involved in replica-
tion licensing and initiation7–9,27,28 (Figure 4). Further
studies to understand the specific role(s) of the encodedember 6, 2018
Figure 4. POLE1 Deficiency Links CDKN1C-IMAGe Syndrome18 with Other Replisome-Associated Disorders
Schematic of replication initiation (adapted by permission fromGaillard et al.22 copyright 2015Macmillan Publishers), highlighting the
sequential action of replisome-associated proteins, mutation of which causes MGS (blue text) and those that are associated with
dwarfism with adrenal insufficiency and/or immune deficiency, including IMAGe syndrome (red text). During replication licensing,
MCM helicases (MCM2-7) are loaded at replication origins by the ORC complex (ORC1-6) with CDC6 and CDT1 to form the pre-repli-
cative complex (pre-RC). Subsequently, loading of additional replisome protein occurs, regulated by DDK and CDK kinases, to form the
pre-initiation complex (pre-IC), that contains the CMG (CDC45, MCMs, GINS) complex. CDKN1C inhibits CDK activity. In the active
replisome, Primase-Pol a initiates DNA synthesis with strands extended by the PCNA-associated DNA polymerases d and ε. POLE1 and
POLE2 are part of the Pol ε holoenzyme.replication proteins during development, along with the
cellular and biochemical basis for the relationship between
CDKN1C and Pol ε, will therefore be of interest.Supplemental Data
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